Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis
Source : https://pubmed.ncbi.nlm.nih.gov/38165333/
This study provides Class I evidence that for patients with gMG, nipocalimab was well-tolerated, and it did not significantly improve MG-ADL at any individual dose but demonstrated a significant dose...
Nipocalimab was generally safe, well tolerated, and showed evidence of dose-dependent reduction in MG-ADL scores after nearly 2 months in this phase 2 study.
Serum Amyloid A Facilitates Expansion of CD4+ T Cell and CD19+ B Cell Subsets Implicated in the Severity of Myasthenia Gravis Patients
Source : https://pubmed.ncbi.nlm.nih.gov/38214332/
Serum amyloid A (SAA) is a clinically useful inflammatory marker involved in the pathogenesis of autoimmune diseases. This study aimed to explore the SAA levels in a cohort of patients...
Serum amyloid A levels in patients with new-onset myasthenia gravis were higher than those in controls and were positively correlated with QMG score, MGFA classification, plasmablast cells, and IL-6/-17 levels.
Altered Serum Levels of Cytokines in Patients With Myasthenia Gravis
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10772159/
Myasthenia gravis (MG) is an autoimmune disease characterized by generalized skeletal muscle contraction weakness due to autoantibodies targeting neural-muscular junctions. Here, we investigated the relationship between key cytokines and MG...
This study revealed that serum Fas levels are increased in patients with myasthenia gravis with AChR and titin antibodies.
Efgartigimod in Generalized Myasthenia Gravis: a Real-Life Experience at a National Reference Center
Source : https://pubmed.ncbi.nlm.nih.gov/38164996/
We observed that EFG was safe and modified significantly the course of the disease along a 14-month follow-up. Our experience strengthens the role of FcRn inhibition as an effective new...
Meaningful clinical improvement in patients treated with efgartigimod was recorded early during the fixed treatment period of an expanded early access program in Italy.
Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10747330/
The pathophysiology of myasthenia gravis (MG) has been largely elucidated over the past half century, and treatment methods have advanced. However, the number of cases of childhood-onset MG is smaller...
The frequency of childhood MG is clearly lower than that of adult-onset MG, and the basic diagnosis and treatment are often chosen to mimic those of adult MG.